Nasdaq Drops Accelrys, Affy, Caliper, Luminex from Biotech Index, adds Genomic Health, Solexa | GenomeWeb
This article has been updated from a previous version to clarify the ICB classification system that Nasdaq uses as part of its criteria for including companies in the Biotechnology Index.
 
NEW YORK, May 15 (GenomeWeb News) - A number of genomics firms have been dropped from the Nasdaq Biotechnology index as part of a semi-annual update, the exchange said on Friday.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Pacific Biosciences is hosting a competition in which researchers are vying to win free sequencing for an organism with the most interesting genome.

An opinion piece appearing in Newsday likens familial DNA searches to stop-and-frisk policies.

The San people of Africa have drawn up a code of conduct for researchers, according to the Conversation.

In Nature this week: genotypes linked to hip osteoarthritis, and more.